Appoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer Both executives possess proven track records in strategic execution and deal-making and will help drive long-term value creation at Galapagos Mechelen, Belgium; July 23, 2025, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointments of Ms. Sooin Kwon as Chief Business Officer (CBO) and Mr. Dan Grossman as Chief Strategy Officer (CStO), effective August 4, 2025, further strengthening the Company ...

New Directors bring deep commercial, operational, and transaction experience to the Board Mechelen, Belgium; July 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointments by way of co-optation of Dawn Svoronos and Jane Griffiths as Non-Executive Independent Directors to its Board of Directors, effective July 28, 2025. Dawn Svoronos and Jane Griffiths will replace Peter Guenter and Simon Sturge, who will step down from the Board on July 28, 2025. Jérôme Contamine, Chair o ...

Appointments of new CEO, CFO, and seasoned business development leaders with proven track records of executing strategic transactions will position the Company to drive shareholder value and advance pipeline expansion Strategic alternatives for the cell therapy business, including a potential divestiture, are being evaluated; CAR-T programs maintain positive momentum with recently presented clinical data Strong balance sheet with €3.1 billion in cash and financial investments as of June 30, 2025Mechelen, Be ...

Core Insights - Galapagos NV has appointed Mr. Aaron Cox as Chief Financial Officer, effective July 7, 2025, succeeding Mr. Thad Huston, who will assist in the transition until July 31, 2025 [1][2] Group 1: Leadership Transition - Aaron Cox brings over 20 years of experience in biotechnology, capital markets, and M&A, having previously served as CFO at Horizon Therapeutics, where he was instrumental in the company's $28 billion acquisition by Amgen [2] - Cox's role at Galapagos will involve leading Finance, Accounting, Tax, Procurement, Communications, and Investor Relations, and he will be part of the Executive Committee [3] Group 2: Strategic Goals - The CEO of Galapagos expressed confidence in Cox's ability to accelerate pipeline growth through business development and disciplined financial management, aiming to create a new pipeline of innovative medicines [3] - Cox emphasized his excitement to join Galapagos at a pivotal moment, focusing on creating shareholder value and advancing innovations for patients [4] Group 3: Company Overview - Galapagos is a biotechnology company dedicated to transforming patient outcomes through innovative science, with a focus on high unmet medical needs and a commitment to delivering results for patients and shareholders [6]

Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin’s Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities Of the 64 patients enrolled, 61 received treatment, resulting in a 5% attrition rate, significantly lower than industry benchmarks. 95% of patients were infused with fresh, stem-like early memory CD19 CAR-T cells, with 89% receiving treatment within 7 days, avoiding the need for cryopreservation and cytotoxic ...

Mechelen, Belgium; May 27, 2025, 22:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 925,000 subscription rights under a new subscription right plan. On May 27, 2025, the Board of Directors of Galapagos approved “Subscription Right Plan 2025 (A)”, intended for personnel of the Company, within the framework of the authorized capital. Under this subscription right plan, 925,000 subscription rights were created, subject to acceptance, fo ...

Mechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that new data from our ongoing ATALANTA-1 Phase 1/2 study of GLPG5101 in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) have been accepted for oral presentations at the 2025 European Hematology Association (EHA) Congress taking place June 12-15, 2025, in Milan, Italy, and the Internation ...

Core Viewpoint - Galapagos is re-evaluating its previously announced separation into two entities due to regulatory and market developments, focusing on maximizing resources for transformative business development transactions [3][4]. Group 1: Strategic Update - The company plans to explore all strategic alternatives for its existing businesses, including cell therapy, to enhance resource allocation for business development [3][4]. - The Board of Directors has appointed Mr. Henry Gosebruch as the new CEO, effective immediately, succeeding Dr. Paul Stoffels, who will retire in April 2025 [4][6]. - Mr. Jérôme Contamine has been appointed as the Chair of the Board of Directors, replacing Dr. Paul Stoffels [5][7]. Group 2: Leadership Transition - Mr. Gosebruch will lead the strategic evaluation process for Galapagos' current business while also focusing on building a pipeline of innovative medicines [4][6]. - Dr. Paul Stoffels will remain with the company in an advisory role, assisting in evaluating strategic options for the cell therapy pipeline, including the flagship program GLPG5101 [6][7]. Group 3: Future Directions - The company is currently assessing strategic options regarding its clinical programs and other assets, including potential mergers, divestitures, and out-licensing [7]. - The goal is to leverage the company's strong balance sheet and cash resources to pursue transformative business development opportunities [4][7].

Group 1 - The article discusses the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and offers a model portfolio of small and mid-cap stocks [1][2] - The service includes over 600 biotech investing articles and live chat features to assist healthcare investors in making informed decisions [2] - A promotional offer is available for new subscribers, including a two-week free trial and a discounted annual subscription price [1] Group 2 - The author previously wrote about Galapagos NV and its potential impact on the biotech landscape with its product GLPG5101 [2] - The article emphasizes the importance of thorough research and analysis in the biotech sector for investment decisions [2]

Core Insights - The first U.S. patient has been dosed in the ATALANTA-1 study of GLPG5101, targeting mantle cell lymphoma (MCL) as the lead indication, with pivotal development planned to start in 2026 and aiming for approval in 2028 [1][2][4] - Significant executive leadership changes are occurring, including the retirement of Dr. Paul Stoffels as CEO and the appointment of Henry Gosebruch as the Founding CEO of the new subsidiary SpinCo [1][12] - As of March 31, 2025, the company reported €3.3 billion in cash and financial investments, with a normalized annual cash burn guidance of €175 million to €225 million reaffirmed [1][20] Clinical Pipeline - The ATALANTA-1 Phase 1/2 study of GLPG5101 is focused on CD19 CAR-T therapy for eight hematological malignancies with high unmet needs, showing promising safety and efficacy in heavily pre-treated patients [3][4] - Enrollment is progressing across European clinical trial sites, with additional cohorts for Richter transformation and chronic lymphocytic leukemia planned for the near future [3][4] Financial Performance - Total net revenues for Q1 2025 were €75.0 million, a 20% increase from €62.4 million in Q1 2024, driven by a significant rise in supply revenues [10][13] - The company reported an operating loss of €158.7 million for Q1 2025, compared to a loss of €33.1 million in Q1 2024, largely due to costs associated with strategic reorganization [11][15] - Cash and cash equivalents totaled €3,297.3 million as of March 31, 2025, reflecting a net decrease of €20.5 million during the first quarter [18][19] Corporate Update - The planned separation of Galapagos into two independent entities, with SpinCo focusing on oncology, immunology, and virology, is expected to be completed by mid-2025 [7][20] - SpinCo will be funded with approximately €2.45 billion in cash and will pursue opportunities to build a pipeline of innovative medicines [7][20] Strategic Initiatives - The company is establishing operations in China to accelerate the development of its next-generation cell therapy pipeline [2][9] - Collaborations with Lonza and Thermo Fisher Scientific are being leveraged to scale up decentralized manufacturing capabilities [9][10]